Prior Authorization Request Form for Sofosbuvir/ Velpatasvir/voxilaprevir (Vosevi)



JOHNS HOPKINS HEALTHCARE

7231 Parkway Drive, Suite 100, Hanover, MD 21076

FAX Completed Form and Applicable Progress Notes to: (410) 424-4037

USFHP Pharmacy Prior Authorization Form

| To be completed by Requesting provider | | |
|--|----------------------|--|
| Drug Name: | Strength: | |
| Dosage/Frequency (SIG): | Duration of Therapy: | |

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

| Step 1 | Please complete patient and physician information (please Patient Name: | | ease print): iician Name: | | | |
|-----------|--|--|---|-----------------------|--|--|
| • | Addres | | Address: | | | |
| | Sponsor ID # | | Phone #: | | | |
| | Date of | f Birth: Se | ecure Fax #: | | | |
| Step | Please complete the clinical assessment: | | | | | |
| 2 | 1. | Is the patient greater than or equal to 18 years of age? | □ Yes | □ No | | |
| | | | Proceed to question 2 | STOP | | |
| | | | | Coverage not approved | | |
| | Does the patient have laboratory evidence of chronic hepatitis C virus (HCV)? | | □ Yes | □ No | | |
| | | | Proceed to question 3 | STOP | | |
| | | | | Coverage not approved | | |
| | 3. Is Vosevi prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician? | □ Yes | □ No | | | |
| | | Proceed to question 4 | STOP | | | |
| | | | Coverage not approved | | | |
| | Has the patient received previous treatment with a HCV regimen containing a NS5A Inhibitor (for example, daclatasvir, elbasvir, ledipasvir, ombitasvir, pibrentasvir, or velpatasvir)? | □ Yes | □ No | | | |
| | | Proceed to question 6 | Proceed to question 5 | | | |
| | 5. Has the patient received previous treatment with a HCV regimen containing sofosbuvir AND has Hepatitis C Genotype 1a or 3 (for example: Harvoni, Epclusa or Sovaldi)? | □ Yes | □ No | | | |
| | | Proceed to question 6 | STOP | | | |
| | | | Coverage not approved | | | |
| | 6. | What is the HCV genotype? | ☐ Genotype 1a - Proceed to | question 7 | | |
| | | | ☐ Genotype 1b or other genotype 1 subtype - Proceed to question 7 | | | |
| | | | ☐ Genotype 2 - Proceed to question 7 | | | |
| | | | ☐ Genotype 3 - Proceed to question 7 | | | |
| | | | ☐ Genotype 4 - Proceed to question 7 | | | |
| | | | ☐ Genotype 5 - Proceed to question 7 | | | |
| | | | ☐ Genotype 6 - Proceed to question 7 | | | |
| | | | ☐ All others - STOP Coverage not approved | | | |

Prior Authorization Request Form for Sofosbuvir/ Velpatasvir/voxilaprevir (Vosevi)

| | | Does the patient does have an estimated glomerular filtration rate (eGFR) less than or equal to 30mL/min or | □ Yes | □ No |
|--------|---------------|---|-------------------------|-----------------------|
| | | end-stage renal disease (ESRD) requiring | STOP | Proceed to question 8 |
| | hemodialysis? | Coverage not approved | | |
| | 8. | Will the patient be receiving concomitant therapy with other hepatitis C drugs or rifampin? | □ Yes | □ No |
| | | other riepatitie o drage of marripin. | STOP | Proceed to question 9 |
| | | | Coverage not approved | |
| | 9. | Will the course of treatment exceed the maximum duration of treatment of 12 weeks? | □ Yes | □ No |
| | | duration of fleatment of 12 weeks? | STOP | Sign and date below |
| | | | Coverage not approved | |
| Step 3 | I certi | fy the above is true to the best of my knowle | dge. Please sign and da | ate: |
| | | Prescriber Signature | Date | |
| | | | | [2 January 2019] |
| | | | | |

| For Internal Use Only | | | | |
|-----------------------|-------------------------------|--|--|--|
| Approved: | Duration of Approval:month(s) | | | |
| Denied: | Authorized By: | | | |
| ☐ Incomplete/Other: | PA#: | | | |
| Date Faxed to MD: | Date Decision Rendered: | | | |